Finally, we examined DDR1 invasive activity and its inhibition by nilotinib in patient‐derived CRC cell lines we recently generated from metastatic tumours and circulating CRC cells in blood samples (Grillet et al, 2017). This evidence concerns the gene DDR1 and neoplasm.